Molecular genetics and diagnosis of thyroid cancer (Q37924088)

25 August 2017

1 reference

title

Molecular genetics and diagnosis of thyroid cancer (English)

1 reference

25 August 2017

0 references

1

Yuri E Nikiforov

1 reference

25 August 2017

2

Marina N Nikiforova

1 reference

25 August 2017

30 August 2011

1 reference

Nature Reviews Endocrinology

25 August 2017

1 reference

25 August 2017

7

1 reference

25 August 2017

10

1 reference

25 August 2017

569-580

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2011.142

25 August 2017

0 references

cites work

Increasing incidence of thyroid cancer in the United States, 1973-2002

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype--papillary, follicular, and anaplastic: a morphological and epidemiological study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

A time trend analysis of papillary and follicular cancers as a function of tumour size: a study of data from six cancer registries in France (1983-2000).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Thyroid cancer in thyroid nodules: finding a needle in the haystack

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Changing trends in thyroid practice: understanding nodular thyroid disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Management guidelines for patients with thyroid nodules and differentiated thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Correlation Between Genetic Alterations and Microscopic Features, Clinical Manifestations, and Prognostic Characteristics of Thyroid Papillary Carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

The two genes generating RET/PTC3 are localized in chromosomal band 10q11.2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Novel tumorigenic rearrangement, Delta rfp/ret, in a papillary thyroid carcinoma from externally irradiated patient

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Fusion of a novel gene, ELKS, to RET due to translocation t(10;12)(q11;p13) in a papillary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

RET/PTC rearrangement in thyroid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

RET oncogene activation in papillary thyroid carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

ret/PTC-1 Activation in Hashimoto Thyroiditis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

High growth rate of benign thyroid nodules bearing RET/PTC rearrangements

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Refined localization of the human TPR gene to chromosome 1q25 by in situ hybridization.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Prevalence of Ras mutations in thyroid neoplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Point mutations of ras oncogenes are an early event in thyroid tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Ras oncogene mutations in benign and malignant thyroid neoplasms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Prevalence of activating ras mutations in morphologically characterized thyroid nodules.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

BRAF Mutation in Papillary Thyroid Carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

BRAF mutations are associated with some histological types of papillary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

BRAF mutation in thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Genetic and biological subgroups of low-stage follicular thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Immunohistochemical and sequencing analyses of the Wnt signaling components in Japanese anaplastic thyroid cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Mutation of the PIK3CA gene in anaplastic thyroid cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Novel germline variants identified in the inner mitochondrial membrane transporter TIMM44 and their role in predisposition to oncocytic thyroid carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Hürthle cell tumours of the thyroid. A review with emphasis on mitochondrial abnormalities with clinical relevance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Solitary, multiple, and familial oxyphil tumours of the thyroid gland

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hürthle cell tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Gene expression in papillary thyroid carcinoma reveals highly consistent profiles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Using gene expression profiling to differentiate benign versus malignant thyroid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

The differentiation of benign and malignant thyroid nodules

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Identification of genes differentially expressed in benign versus malignant thyroid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

The role of microRNA genes in papillary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

MicroRNA expression profiles in thyroid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

MicroRNA deregulation in human thyroid papillary carcinomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Thyroid hormone receptor beta (THRB) is a major target gene for microRNAs deregulated in papillary thyroid carcinoma (PTC)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Specific microRNAs are downregulated in human thyroid anaplastic carcinomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Gene methylation in thyroid tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Downregulation of Rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Epigenetics of thyroid cancer and novel therapeutic targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to gamma-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Preferential induction of RET/PTC1 rearrangement by X-ray irradiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Interphase chromosome folding determines spatial proximity of genes participating in carcinogenic RET/PTC rearrangements

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Proximity ofTPRandNTRK1Rearranging Loci in Human Thyrocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Fragile and unstable chromosomes in cancer: causes and consequences

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Epidemiology of thyroid diseases in iodine sufficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Papillary thyroid cancer incidence in the volcanic area of Sicily.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Global cancer statistics, 2002

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Diagnosis of "follicular neoplasm": a gray zone in thyroid fine-needle aspiration cytology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Management of a solitary thyroid nodule

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Molecular diagnostics and predictors in thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

BRAF V600E mutation analysis of thyroid nodules needle aspirates in relation to their ultrasongraphic classification: a potential guide for selection of samples for molecular analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Diagnostic value of pyrosequencing for the BRAF V600E mutation in ultrasound-guided fine-needle aspiration biopsy samples of thyroid incidentalomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Contribution of molecular testing to thyroid fine-needle aspiration cytology of “follicular lesion of undetermined significance/atypia of undetermined significance”

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Assessment of RET/PTC1 and RET/PTC3 rearrangements in fine-needle aspiration biopsy specimens collected from patients with Hashimoto's thyroiditis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

The prevalence and prognostic value of BRAF mutation in thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I− targeting to the membrane

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

BRAF Mutations in Papillary Thyroid Carcinomas Inhibit Genes Involved in Iodine Metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Prognostic utility of BRAF mutation in papillary thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

BRAFV600E mutation and p27kip1 expression in papillary carcinomas of the thyroid ≤1 cm and their paired lymph node metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

BRAF(V600E) mutation and the biology of papillary thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Small papillary thyroid cancers—is BRAF of prognostic value?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

HMGA2 gene expression analysis performed on cytologic smears to distinguish benign from malignant thyroid nodules

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

A prospective study evaluating the accuracy of using combined clinical factors and candidate diagnostic markers to refine the accuracy of thyroid fine needle aspiration biopsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Molecular classification of thyroid nodules using high-dimensionality genomic data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Development of a microRNA-based molecular assay for the detection of papillary thyroid carcinoma in aspiration biopsy samples.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.142

Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors.

31 March 2020

1 reference

12 December 2020

A novel type of RET rearrangement (PTC8) in childhood papillary thyroid carcinomas and characterization of the involved gene (RFG8)

1 reference

12 December 2020

Detection of a novel type of RET rearrangement (PTC5) in thyroid carcinomas after Chernobyl and analysis of the involved RET-fused gene RFG5.

1 reference

12 December 2020

Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children.

1 reference

12 December 2020

Follicular lesions of thyroid: a 5-year fine-needle aspiration experience

1 reference

12 December 2020

Detection of retTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method

1 reference

12 December 2020

Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas

1 reference

12 December 2020

In vitro irradiation is able to cause RET oncogene rearrangement

1 reference

12 December 2020

RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes

1 reference

12 December 2020

TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas

1 reference

12 December 2020

The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults

1 reference

12 December 2020

RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults

1 reference

12 December 2020

Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features

1 reference

12 December 2020

Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications

1 reference

12 December 2020

RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features.

1 reference

12 December 2020

Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland

1 reference

12 December 2020

Presence of mutations in all three ras genes in human thyroid tumors

1 reference

12 December 2020

The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids

1 reference

12 December 2020

Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells

1 reference

12 December 2020

Minireview: branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid

1 reference

12 December 2020

Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas

1 reference

12 December 2020

Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma

1 reference

12 December 2020

Translocation t(10;14)(q11.2:q22.1) fusing the kinetin to the RET gene creates a novel rearranged form (PTC8) of the RET proto-oncogene in radiation-induced childhood papillary thyroid carcinoma

1 reference

12 December 2020

The human tropomyosin gene involved in the generation of the TRK oncogene maps to chromosome 1q31

1 reference

12 December 2020

High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma

1 reference

12 December 2020

Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice

1 reference

12 December 2020

A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma

1 reference

12 December 2020

Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma

1 reference

12 December 2020

Common fragile sites and cancer: targeted cloning by insertional mutagenesis

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2011.142

1 reference

PubMed ID

21878896

Dimensions Publication ID

25 August 2017

0 references

1 reference

PubMed ID

21878896